中国中医眼科杂志2025，Vol.35Issue(3)：201-207,7.DOI:10.13444/j.cnki.zgzyykzz.2025.03.001
中成药治疗视网膜色素变性临床应用指南
Clinical Application Guidelines for Chinese Patent Medicines in the Treatment of Retinitis Pigmentosa
摘要
Abstract
Retinitis pigmentosa(RP)is one of the common irreversible blinding eye diseases in ophthalmology.Currently,there is a lack of approved drugs or non-medicine therapies to stop the progression of RP or cure it.Previous studies have shown that Chinese patent medicines have achieved good efficacy in the treatment of RP.However,in China,there is a lack of a standardized plan to guide the treatment of RP with Chinese patent medicines.Under the guidance of the principle of"evidence-based as the main,consensus as the supplement,and experience as a reference",through extensive literature retrieval and expert consensus discussions,this guideline has formed three recommendations regarding the main clinical problems,effectiveness,safety,usage methods,and recommendation strength that occur during the use of Chinese patent medicines in the treatment of RP.The aim is to standardize and promote the rational application of Chinese patent medicines in RP,delay the disease progression of RP patients,improve their quality of life,and reduce the blindness rate.关键词
中成药/视网膜色素变性/临床应用指南Key words
Chinese patent medi-cines/retinitis pigmentosa/clinical ap-plication guidelines分类
医药卫生引用本文复制引用
《中成药治疗优势病种临床应用指南》标准化项目组,梁丽娜..中成药治疗视网膜色素变性临床应用指南[J].中国中医眼科杂志,2025,35(3):201-207,7.基金项目
1国家自然科学基金项目(82274589) 2国家中医药管理局《中成药治疗优势病种临床应用指南》标准化项目(SATCM-2015-BZ402) 3中国中医药循证医学中心"业务研究室主任专项"创建中医药循证决策模式和体系研究(2020YJSZX-2) 4中国中医科学院科技创新工程重大攻关项目(CI2021A02602) 5中国中医科学院眼科医院中央高水平医院项目(GSP3-03、GSP5-82、GSP2-19) （82274589）
